Compare · MDLN vs NVCR
MDLN vs NVCR
Side-by-side comparison of Medline Inc. (MDLN) and NovoCure Limited (NVCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVCR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 28.7x NVCR ($1.68B).
- Over the past year, MDLN is down 11.8% and NVCR is down 2.8% - NVCR leads by 9.0 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 3 for NVCR).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- NovoCure Limited
- Price
- $35.95-1.74%
- $14.08-2.26%
- Market cap
- $48.08B
- $1.68B
- 1M return
- +11.97%
- -15.81%
- 1Y return
- -11.77%
- -2.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 7
- 3
- Recent ratings
- 25
- 25
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest NVCR
- NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
- Novocure to Report Third Quarter 2026 Financial Results
- NovoCure Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Novocure Announces Upcoming Investor Events
- NovoCure Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by NovoCure Limited
- Novocure Reports Second Quarter 2026 Financial Results
- Analyst resumed coverage on NovoCure with a new price target